NOVO — Februar 2022
-
Novo/Sydbank: Prognosen bør tilfredse markedet - ser aktien stige
https://www.proinvestor.com/investornyt/774813/novo-sydbank-prognosen-bor-tilfredse-markedet-ser-aktien-stige -
Novo Q4: Ozempic passerer 10 mia. kr. i salg på et kvartal - NY
https://www.proinvestor.com/investornyt/774815/novo-q4-ozempic-passerer-10-mia-kr-i-salg-pa-et-kvartal-ny -
KORR: Novo Q4: Sigter over analytikernes prognose for 2022 - NY
https://www.proinvestor.com/investornyt/774820/korr-novo-q4-sigter-over-analytikernes-prognose-for-2022-ny -
Novo/CEO: Har forbedret intern fyldekapacitet for Wegovy
https://www.proinvestor.com/investornyt/774829/novo-ceo-har-forbedret-intern-fyldekapacitet-for-wegovy -
Novo OVERBLIK Q4: Stærk prognose opvejer skuffende drift
https://www.proinvestor.com/investornyt/774945/novo-overblik-q4-staerk-prognose-opvejer-skuffende-drift -
Novo/CFO: Ser stabil driftsmargin i de kommende år
https://www.proinvestor.com/investornyt/774972/novo-cfo-ser-stabil-driftsmargin-i-de-kommende-ar -
Novo/CEO: 2025-mål for fedmeforretning er klart inden for rækkevidde
https://www.proinvestor.com/investornyt/775006/novo-ceo-2025-mal-for-fedmeforretning-er-klart-inden-for-raekkevidde -
Novo/CEO: Læren af Wegovy-problemer kan være større lagre
https://www.proinvestor.com/investornyt/775043/novo-ceo-laeren-af-wegovy-problemer-kan-vaere-storre-lagre -
Novo/SHB: Kursmål løftes til 710 kr. fra 650 kr. - NY
https://www.proinvestor.com/investornyt/775614/novo-shb-kursmal-loftes-til-710-kr-fra-650-kr-ny -
-
Novo Nordisk/Jyske Bank: Anbefaling hæves til "køb" fra "hold"
https://www.proinvestor.com/investornyt/775629/novo-nordisk-jyske-bank-anbefaling-haeves-til-kob-fra-hold -
Novo Nordisk/DNB: Kursmål hæves til 780 kr. fra 740 kr.
https://www.proinvestor.com/investornyt/775645/novo-nordisk-dnb-kursmal-haeves-til-780-kr-fra-740-kr -
Denne ugekommentar dedikerer Helge Larsen til biotech, nærmere bestemt den nedtur, sektoren har oplevet og stadig oplever. Han kigger bl.a. ned i mulige årsager som rentestigninger, sektorrotation - men også over på markedet i USA med NBI-indekset og mekanismerne her. https://www.proinvestor.com/boards/100739/Ugekommentaren-Nedturen-i-biotech
-
Novo Nordisk: Topledelse sælger ud efter tildelelse af aktier https://proinvestor.com/investornyt/776726/novo-nordisk-topledelse-saelger-ud-efter-tildelelse-af-aktier
-
Novo: Ser opkøbsmuligheder i kursfald i biotek - GENT https://proinvestor.com/investornyt/777275/novo-ser-opkobsmuligheder-i-kursfald-i-biotek-gent
-
Here's How Healthcare Stocks Have Historically Performed After a Down January https://www.proinvestor.com/investornyt/780839/heres-how-healthcare-stocks-have-historically-performed-after-a-down-january
-
Novo Nordisk: Blackrock øger aktiepost til over 5 pct. https://proinvestor.com/investornyt/781113/novo-nordisk-blackrock-oger-aktiepost-til-over-5-pct
-
C-25 selskaber - Karakterbogen for 4. kvartal: https://www.proinvestor.com/index.php?p=debat_1&postid=101136
-
Novo: Amerikansk salgsdirektør skifter til Leo Pharma https://proinvestor.com/investornyt/783412/novo-amerikansk-salgsdirektor-skifter-til-leo-pharma
-
Henrik Poulsen står til at avancere i Novo Nordisks bestyrelse - NY https://proinvestor.com/investornyt/784780/henrik-poulsen-star-til-at-avancere-i-novo-nordisks-bestyrelse-ny
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind